Wagstaff, J., Attard, G., Murphy, L., Clarke, N. W., Sachdeva, A., Jones, C., . . . Durr, D. (2023). Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: Final results from two randomised phase 3 trials of the STAMPEDE platform protocol. The Lancet Oncology, 24(5), pp. 443-456. doi:10.1016/s1470-2045(23)00148-1

Wagstaff, John, et al. "Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide for Patients With Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results From Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol." The Lancet Oncology 24, no. 5 (2023): 443-456.

Wagstaff, John, et al. "Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide for Patients With Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: Final Results From Two Randomised Phase 3 Trials of the STAMPEDE Platform Protocol." The Lancet Oncology 24.5 (2023): 443-456.